EGFR and glioma: The dependency of our predictor classification to commonly used grade II/III glioma prognostic factors (1p19q loss of heterozygosity, IDH1 gene mutation and EGFR gene amplification) was analyzed using the NL validation cohort for which these molecular data were available.